| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.18B | — |
| Cost of Revenue | $1.18B | — |
| R&D Expense | $70.7M | — |
| SG&A Expense | $382.6M | — |
| Pre-tax Income | -$861.9M | — |
| Income Tax | -$131.0M | — |
| Net Income | -$730.9M | — |
| EPS (Basic) | -$9.60 | — |
| EPS (Diluted) | -$9.60 | — |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $387.2M | — |
| Accounts Receivable | $415.9M | — |
| Inventory | $527.7M | — |
| Current Assets | $1.48B | — |
| Total Assets | $4.35B | — |
| Current Liabilities | $515.0M | — |
| Long-term Debt | $2.44B | — |
| Stockholders' Equity |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $113.4M | — |
| Capital Expenditures | $37.0M | — |
| Investing Cash Flow | -$20.9M | — |
| Financing Cash Flow | -$12.9M | — |
| Free Cash Flow | $76.4M | — |
| $1.25B |
| — |